MBC-11

MBC-11 is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC). MBC-11 has the potential for tumor-induced bone disease (TIBD) research^[1]. In Vitro: MBC-11 shows similar activity profiles and significantly inhibits growth of all three cell lines between 10^-8 and 10^-4 M. MBC-11 decreases KAS-6/1 cell growth from approximately 56% at 10^-8 M to 6% at 10^-5 M^[1]. In Vivo: MBC-11 (0.04 μg/day, s.c.) has a lower incidence of bone metastases of 40% compared to those treated with PBS (90%) or 0.04 μg/day zoledronate (100%). MBC-11 also significantly decreases bone tumor burden compared to PBS- or zoledronate-treated mice^[1].
Weight gained in mice treated with up to 500 μg/day of MBC-11 is similar to the PBS treated group^[1].
These results demonstrate that MBC-11 decreases bone tumor burden, maintains bone structure, and may increase overall survival, warranting further investigation as a treatment for tumor-induced bone disease (TIBD)^[1].